Figure 1.

Effect of per os presymptomatic treatment with 3HFWC nanosubstance on amyloid plaque burden, neuroinflammation, and synaptic plasticity in 5×FAD animal Alzheimer's disease model.

(A) Experimental design: 5×FAD animals were treated with 3HFWC for three months starting at the postnatal day 21. (B) Amyloid plaque burden was analyzed in the anterior and posterior cortex, and a decrease of 14% and 20%, respectively, was observed after the 3HFWC treatment. (C) The analyses conducted after three months of 3HFWC treatment showed that amyloid plaque burden was reduced, neuroinflammation was not induced, and synaptic vulnerability was not incited. *P < 0.05. Unpublished data. Created with Microsoft PowerPoint. 3HFWC: Harmonized-hydroxylated fullerene-water complex; P0: postnatal day zero.